Clinical Trial Update: An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide [Phase 2]

View source ↗

Summary

Phase 2 open-label study evaluating the incidence and severity of diarrhea in early-stage HER2-positive breast cancer patients treated with neratinib and lopera…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Loperamide (loperamide)
• neratinib (neratinib)

Snippet

Sponsor: Puma Biotechnology, Inc. | Conditions: Early Stage HER2+ Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2022-05-06